Icahn School of Medicine Myeloid Malignancy Workshop 2025

+ Include: 10 videos + 1 pdf, size: 3.48 GB

+ Target Audience: hematologists, oncologists

+ Information:

This workshop will include speakers with international recognition for excellence in science and clinical care of myeloid malignancies. Given the relative rarity of each disease, rapid pace of scientific discovery over the last several years, recent approval of novel agents, and the multitude of investigational agents in late-stage clinical development it is imperative to provide cutting edge updates in a focused manner. The target audience for this CME-accredited event will include clinical and laboratory-based physicians, trainees, laboratory investigators, pharmacists, nurses, nurse practitioners, physician assistants, and patients. The event would take place in a lecture hall on the campus of Mount Sinai. The talks will be 30 minutes in duration and followed by 10-minute question and answer sessions. The event will be moderated by John Mascarenhas, Marina Kremyanskaya and Ruben Mesa and the audience will be encouraged to participate in Q&A sessions. Additionally, there will be audience response system (ARS) questions before and after to gauge impact on learning.

1. Understand modern laboratory tools for exploring myeloid malignancy pathway for therapeutic targeting
2. Recognize the appropriate evidence-based therapies for patients with myeloid leukemia
3. Understand complex cellular mechanisms driving thrombosis in myeloproliferative neoplasms
4. Identify patient specific approaches and therapeutic options for patients with myelodysplastic syndromes
5. Discuss the emerging results of laboratory and clinical studies providing insights into biology and potential interventions in CHIP/CCUS
6. Identify treatment goals for systemic mastocytosis that incorporate next generation kit inhibitors.

The Icahn School of Medicine’s Myeloid Malignancy Workshop 2025 is best for hematologists, oncologists, clinician-scientists, fellows, and researchers focused on myeloid cancers who want cutting-edge updates on diagnostics, therapeutics, and clinical trials.